Effect of Kligman plus Methimazol in treatment of melasma

Phase 3

Recruiting

• Conditions: Melasma.; Chloasma; L81.1

• Registration Number: IRCT20200817048437N1
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 6 October 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 44

Inclusion Criteria

All patients with melasma

Exclusion Criteria

pregnancy
lactation
Treatment with OCP and HRT
Use of drugs that darken the color of the skin
History of allergy to topical and systemic steroids and thyroid drugs in at least the last 30 days
History of Severe systemic disease
History of any thyroid disease

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The severity of melasma lesions is measured according to the The Melasma area and severity index (MASI) , which includes three factors: percentage of facial involvement, darkness and homogeneity. Timepoint: Measurement of the Melasma area and severity index (MASI score) at the beginning of the study and 8 weeks after the start of the drug intervention. Method of measurement: The Melasma area and severity index (MASI).